Efficacy of 0.1% cyclosporine eye drops in Sjögren syndrome dry eye

Abstract

AbstractPurposeTo investigate the efficacy of the 0.1% cycloporin A (Ikervis®) are compared with those of the conventional 0.1% cycloporin A emulsion (Restasis®) in primary Sjögren syndrome dry eye.MethodsThis study included 50 eyes of 25 patients diagnosed with primary SS. Patients had been using 0.05% cyclosporin eye drops (Restasis®) administered twice daily for more than 6 months with artificial tears and their ocular surface stain scoring was more than 3 by SICCA (풀어서 써 주세요) grading. The patients were instructed to change 0.05% cyclosporin A emulsion (Restasis®) twice into 0.1% cycloporin A (Ikervis®) once a day with maintenance of same artificial tears. The changes from baseline in dry eye parameters including tear breakup time (BUT), Schirmer I value, corneal staining score, and conjunctival staining score by The Sjögren's International Collaborative Clinical Alliance (SICCA) and Ocular Surface Disease Index (OSDI) at 3 months were evaluated.ResultsPatients were all women and mean age were 53.4 ± 10.1 years. At 3 months, BUT was improved from 3.81 to 4.10 seconds with no significant difference (p = 0.41). Schirmer I value and OSDI did not significantly change from baseline. Corneal and conjunctival staining scores were significantly improved after change of Restasis® into Ikervis® in SS dry eyes (p = 0.001 and p = 0.022, respectively).ConclusionsTreatment with 0.1% cyclosporine Ikervis® might be more effective to alleviate ocular surface staining scores than 0.05% cyclosporine Restasis® in primary SS dry eye. Further study with longer treatment would be needed.